Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H28O6 |
Molecular Weight | 400.4648 |
Optical Activity | ( - ) |
Additional Stereochemistry | Yes |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
Stereo Comments | AXIAL, S |
SHOW SMILES / InChI
SMILES
COC1=C(OC)C(OC)=C2C(C[C@@H](C)[C@@H](C)CC3=C2C(OC)=C4OCOC4=C3)=C1
InChI
InChIKey=RTZKSTLPRTWFEV-OLZOCXBDSA-N
InChI=1S/C23H28O6/c1-12-7-14-9-16(24-3)20(25-4)22(26-5)18(14)19-15(8-13(12)2)10-17-21(23(19)27-6)29-11-28-17/h9-10,12-13H,7-8,11H2,1-6H3/t12-,13+/m1/s1
Molecular Formula | C23H28O6 |
Molecular Weight | 400.4648 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Gomisin N is the most abundant dibenzocyclooctadiene lignan present in the traditional Chinese medicinal herb Schisandra chinensis (Turcz.) Baill. In vitro assays demonstrated that Gomisin N could inhibit TGF-β induced epithelial-mesenchymal transition of 4T1 cells and of primary human breast cancer cells. Gomisin N could maintain membrane stability of rat hepatocytes under oxidative stress. Gomisin N can reduce inflammation, inhibit apoptosis, and improve cardiac function after ischemic injury. It represents a potential novel therapeutic approach for treatment of ischemic heart disease. Gomisin N produced beneficial sedative and hypnotic bioactivity, which might be mediated by the modification of the serotonergic and GABAergic system.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0034439 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1442110 |
|||
Target ID: map04350 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22848381 |
|||
Target ID: WP1290 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24260217 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Inhibitory effect of schisandrin B on gastric cancer cells in vitro. | 2007 Dec 28 |
|
Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling. | 2007 Nov 15 |
|
The Nrf2-ARE pathway is associated with Schisandrin b attenuating benzo(a)pyrene-Induced HTR cells damages in vitro. | 2016 Nov |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22848381
Mice: 100, 30, or 10 mg/kg body weight every day for a total of 7 doses.
Route of Administration:
Intragastric
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1442110
Malondialdehyde (MDA) formation markedly increased after the plasma of rat hepatocytes incubated with Fe2+/cysteine or Vitamin C/NADPH for 30min.Addition of Schisandrin B to the incubation mixture significantly inhibited MDA production. The inhibitory rates of MDA formation by Schisandrin B were 69 and 78, respectively.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:29:16 GMT 2023
by
admin
on
Sat Dec 16 10:29:16 GMT 2023
|
Record UNII |
DKO6O75Z5V
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
158103
Created by
admin on Sat Dec 16 10:29:16 GMT 2023 , Edited by admin on Sat Dec 16 10:29:16 GMT 2023
|
PRIMARY | |||
|
69176-52-9
Created by
admin on Sat Dec 16 10:29:16 GMT 2023 , Edited by admin on Sat Dec 16 10:29:16 GMT 2023
|
PRIMARY | |||
|
DKO6O75Z5V
Created by
admin on Sat Dec 16 10:29:16 GMT 2023 , Edited by admin on Sat Dec 16 10:29:16 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |